Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MH3D is a biotechnology company specializing in advanced 3D bioprinting and microfluidic technologies for tissue engineering and drug discovery. The company's core innovation is a proprietary micro-hydrodynamic 3D printing platform that enables the high-resolution fabrication of complex, multi-material biological structures. Their product portfolio includes versatile bioprinters, specialized bioinks, and sophisticated organ-on-a-chip models designed to mimic human physiological environments. These technologies are utilized by researchers and pharmaceutical companies to improve the accuracy of drug screening and reduce the necessity for animal testing. MH3D also focuses on clinical applications, such as developing bio-printed scaffolds for wound healing and regenerative medicine. Based in Victoria, Canada, the company is a spin-off from the University of Victoria and continues to collaborate with academic and industrial partners to advance the field of biofabrication.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on MH3D.